Yonggui Tian
Overview
Explore the profile of Yonggui Tian including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
233
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tian Y, Zhang L, Ping Y, Zhang Z, Yao C, Shen C, et al.
Cancer Immunol Immunother
. 2025 Jan;
74(2):55.
PMID: 39751840
Chimeric antigen receptor (CAR) T cell therapy for solid tumors faces significant challenges, including inadequate infiltration, limited proliferation, diminished effector function of CAR T cells, and an immunosuppressive tumor microenvironment...
2.
Tian Y, Wen C, Zhang Z, Liu Y, Li F, Zhao Q, et al.
Cancer Immunol Immunother
. 2022 Mar;
71(11):2663-2675.
PMID: 35352167
Chimeric antigen receptor (CAR) T cells remain unsatisfactory in treating solid tumors. The frequency of tumor-infiltrating T cells is closely related to the good prognosis of patients. Augmenting T cell...
3.
Liu Y, Zhang Z, Tian Y, Wang D, Liu S, Li L, et al.
Cytotherapy
. 2022 Feb;
24(5):526-533.
PMID: 35219583
Background Aims: In this retrospective clinical study, the authors investigated the impact of cytokine-induced killer (CIK) cell-based immunotherapies on the long-term survival of patients with esophageal squamous cell carcinoma (ESCC)....
4.
Shen C, Zhang Z, Tian Y, Li F, Zhou L, Jiang W, et al.
BMC Med
. 2021 Nov;
19(1):283.
PMID: 34819055
Background: Chimeric antigen receptor T (CAR-T) cell therapy has limited effects in the treatment of solid tumors. Sulforaphane (SFN) is known to play an important role in inhibiting tumor growth,...
5.
Shen C, Liu C, Zhang Z, Ping Y, Shao J, Tian Y, et al.
Front Immunol
. 2021 Jul;
12:680055.
PMID: 34194433
Background: There is increasing evidence that group 2 innate lymphoid cells (ILC2s) play an essential role in allergy and parasitic infection. However, the role of ILC2s in human lung cancer...
6.
Zhang Z, Chen X, Tian Y, Li F, Zhao X, Liu J, et al.
J Immunother Cancer
. 2020 Oct;
8(2).
PMID: 33023981
Background: Tumor relapse due to mutation in can hinder the efficacy of chimeric antigen receptor (CAR)-T cell therapy. Herein, we focused on lymphoma patients whose B cells exhibited a point...
7.
Tian Y, Li Y, Shao Y, Zhang Y
J Hematol Oncol
. 2020 May;
13(1):54.
PMID: 32423475
Immunotherapies have become the backbone of cancer treatment. Among them, chimeric antigen receptor (CAR) T cells have demonstrated great success in the treatment of hematological malignancies. However, CAR T therapy...
8.
Zhang Z, Li F, Tian Y, Cao L, Gao Q, Zhang C, et al.
J Immunol
. 2020 Mar;
204(9):2575-2588.
PMID: 32221038
Metformin has been studied for its anticancer effects by regulating T cell functions. However, the mechanisms through which metformin stimulates the differentiation of memory T cells remain unclear. We found...